An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

Marc Salzberg,Christoph Rochlitz,Rudolf Morant,George N. Thalmann,Augusto Pedrazzini,Enrico Roggero,Astrid Schönenberger,Alexander Knuth,Markus Borner

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

2007

Marc Salzberg
Christoph Rochlitz
Rudolf Morant
George N. Thalmann
Augusto Pedrazzini
Enrico Roggero
Astrid Schönenberger
Alexander Knuth
Markus Borner

Prostate cancer is the most common type of cancer in men, however, therapeutic options are limited. 50-90% of hormone-refractory prostate cancer cells show an overexpression of epidermal growth fac

Keywords:

Refractory
Phases of clinical research
Cancer
Epidermal growth factor receptor
Gefitinib
Prostate cancer
Oncology
Tyrosine-kinase inhibitor
Medicine
Internal medicine
Docetaxel
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations